We are live on ! Find out more
PACB icon

Pacific Biosciences

132 hedge funds and large institutions have $361M invested in Pacific Biosciences in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 43 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 43

1.61% more ownership

Funds ownership: 75.28%76.89% (+1.6%)

8% less funds holding

Funds holding: 143132 (-11)

14% less call options, than puts

Call options by funds: $989K | Put options by funds: $1.15M

37% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 30

39% less capital invested

Capital invested by funds: $592M → $361M (-$231M)

Holders
132
Holders Change
-11
Holders Change %
-7.69%
% of All Funds
2.91%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
19
Increased
52
Reduced
43
Closed
30
Calls
$989K
Puts
$1.15M
Net Calls
-$160K
Net Calls Change
+$590K
Name Holding Trade Value Shares
Change
Change in
Stake
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
26
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$3.5M -$6.76M -1,650,042 -59%
JP Morgan Chase
27
JP Morgan Chase
New York
$3.33M +$3.22M +786,673 +261%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.27M +$3.51K +858 +0.1%
CS
29
Credit Suisse
Switzerland
$3.22M +$2.25M +548,503 +109%
GCIA
30
Gabelli & Co Investment Advisers
New York
$2.91M +$147K +35,825 +4%
Charles Schwab
31
Charles Schwab
California
$2.7M +$71.8K +17,531 +2%
Public Sector Pension Investment Board (PSP Investments)
32
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$2.45M -$4.41M -1,076,774 -57%
Aviva
33
Aviva
United Kingdom
$2.25M +$1.52M +372,159 +103%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$2.09M -$277K -67,600 -9%
CS
35
Candriam SCA
Luxembourg
$2.07M
SCM
36
Segantii Capital Management
Hong Kong
$1.95M +$978K +238,826 +60%
N
37
Nuveen
North Carolina
$1.75M +$80.2K +19,593 +4%
BLAM
38
Bourne Lent Asset Management
New York
$1.7M +$470K +114,750 +26%
PIM
39
Platinum Investment Management
Australia
$1.53M +$1.03M +252,221 +102%
TCM
40
Tekla Capital Management
Massachusetts
$1.52M
Ameriprise
41
Ameriprise
Minnesota
$1.35M -$2.36M -577,395 -57%
LOAMU
42
Lombard Odier Asset Management (USA)
New York
$1.25M -$185K -45,253 -10%
GI
43
GAMCO Investors
Connecticut
$1.15M -$145K -35,314 -9%
MOACM
44
Mutual of America Capital Management
New York
$1.1M +$187K +45,740 +15%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$968K -$13.5K -3,300 -1%
HA
46
Havens Advisors
New York
$945K +$1.23M +300,293 +3,587%
HA
47
Heartland Advisors
Wisconsin
$918K +$1.23M +300,000 New
Swiss National Bank
48
Swiss National Bank
Switzerland
$772K +$13.9K +3,400 +1%
Group One Trading
49
Group One Trading
Illinois
$660K +$628K +153,404 +246%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$658K -$9.93K -2,426 -1%

PACB Hedge Fund Activity: Q1 2020 in Review

132 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2020, worth a combined $361M — down 39% from $592M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PACB and 19 opened new positions — a net loss of 11 holders — while 43 trimmed existing stakes and 52 added.

The largest buyer was Kite Lake Capital Management (UK), opening a new position worth an estimated $22.5M. The largest seller was AQR Arbitrage, exiting entirely with an estimated $35.7M sold.

  • 132 institutional investors held Pacific Biosciences (PACB) as of Q1 2020, down from 143 in Q4 2019.
  • Funds reported $361M of Pacific Biosciences stock for Q1 2020, down 39% quarter-over-quarter.
  • 19 funds opened new Pacific Biosciences positions in Q1 2020 and 30 closed out, a net change of -11 holders.
  • The largest Pacific Biosciences buyer in Q1 2020 was Kite Lake Capital Management (UK), an estimated $22.5M added.
  • The largest Pacific Biosciences seller in Q1 2020 was AQR Arbitrage, an estimated $35.7M sold.

Based on aggregated 13F filings for Q1 2020.